BG Medicine's heart failure Dx wins higher CMS coverage; Blood test to screen for presymptomatic Alzheimer's advances;

> BG Medicine's ($BGMD) stock price doubled Dec. 10 after the Centers for Medicare and Medicaid Services nearly doubled the reimbursement price for the company's test that allows for early detection of chronic heart failure. Story

> King's College London researchers said they've made major progress on a blood test that could screen for Alzheimer's before clinical symptoms appear. Story

> Navidea Biopharmaceuticals ($NAVB) won special designation from the FDA to expedite a supplemental new drug application to use Lymphoseek injection to help map lymph nodes in patients with head and neck cancer. Item

> Bermuda's Health Ministry is considering rules that would require precertification before patients can undergo medical diagnostic procedures. Story

> Home diagnostic testing devices could help monitor epilepsy drug levels, according to two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington, D.C. Item

> Viracor-IBT, a specialty diagnostics lab focused on immunology, infectious disease and allergy testing, has snatched up the National Institute of Transplantation's Los Angeles-based serology and HLA laboratory operations. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.